Abstracts tagged "Demographics"

Abstract Number: 2615 • ACR Convergence 2025
The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection
Manush Sondhi¹, Bhavik Bansal², Hemant Khandelia¹, Jiha Lee³, Sebastian E Sattui⁴, Siddharth Singh⁵ and Namrata Singh⁶, ¹University of Washington, Seattle, WA, ²UT Southwestern Medical Center, Dallas, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵University of California San Diego, San Diego, CA, ⁶University of Washington, Bellevue, WA
Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…
Abstract Number: 1012 • ACR Convergence 2025
Racial and Gender Disparities in Gout Clinical Trials
Fizza Zulfiqar¹, Dania Kaur², Meaghan Bethea³, Taylor Spencer⁴, Samhitha Bitla⁵, Abhinav Vyas⁶ and Camelia Arsene⁷, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²North Alabama Medical Center, Muscle Shoals, AL, ³Trinity Health Oakland Hopsital, Pontiac, MI, ⁴Trinity Health Oaklnd Hospital, Pontiac, MI, ⁵Trinity Health Oakland Hospital, Pontiac, MI, ⁶Vanderbilt University, Nashvile, TN, ⁷Trinity Health Oakland Hospital, Pontiac
Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
Abstract Number: 2558 • ACR Convergence 2025
Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions
Leslie Myers¹, Elizabeth Neal², Edward O'Bryan¹, Michele Way³ and Timothy Walton¹, ¹CSI Pharmacy, Nash, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Olathe, KS
Background/Purpose: Home infusion therapy is an established alternative site of care for patients requiring administration of infusion medications through a needle or catheter. Supported by…
Abstract Number: 0703 • ACR Convergence 2025
Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
Nicolas Barnechea Alvarado¹, Khadija Mohib¹, Rameez Qasim² and Muhammad Ali³, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Dow International Medical College, Karachi, Sindh, Pakistan
Background/Purpose: Systemic sclerosis is one of the most fatal rheumatologic diseases, with significantly higher mortality rates compared to the general population, likely due to its…
Abstract Number: 2537 • ACR Convergence 2025
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
Merav Heshin Bekenstein¹, Tali Elbaz², Yael Illous² and Barak Kandell³, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv, Israel, ³The Academic College of Tel Aviv-Yafo, Tel Aviv, Israel
Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…
Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
Abstract Number: 2099 • ACR Convergence 2025
Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
Khadija Mohib¹, Rameez Qasim², Nicolas Barnechea Alvarado¹, ZAUHA FAWAD MEMON³ and Muhammad Asjad Saleem⁴, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, ⁴Indus Hospital Karachi, Karachi
Background/Purpose: Osteoarthritis (OA) is the most prevalent musculoskeletal condition, predominantly affecting individuals over the age of 55. According to the World Health Organization (WHO), OA…
Abstract Number: 0607 • ACR Convergence 2025
Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort
Daniel Goldman¹, Andrea Fava², Laurence Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The demographics of our lupus cohort have shifted over the decades towards an older population. While much of the shift can be attributed to…
Abstract Number: 2088 • ACR Convergence 2025
Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020
Ghassan Makhoul¹, Aziz-ur-Rahman Khalid², Hasan Munshi¹, Islam Rajab¹, MD Walid Akram Hussain¹, Reshma John¹, Elvira Assaf¹, Amer Al Badawy¹, Barbare Khatiashvili¹, Rouba Isshak¹, Nargis Mateen³ and Robert Lahita⁴, ¹St. Josephs University Medical Center, Paterson, ²St. Joseph's University Medical Center, wayne, ³St. Josephs University Medical Center, Paterson, NJ, ⁴St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability and pain in older adults. While not traditionally viewed as fatal, OA contributes significantly to morbidity…
Abstract Number: 0579 • ACR Convergence 2025
Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting the joints, skin, and other regions of the body. It impacts up to 36%…
Abstract Number: 1996 • ACR Convergence 2025
Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.
Cristina RodrÍguez-Alvear¹, Fernando Borrás² and Mariano Andrés³, ¹Virgen de la Peña General Hospital, Fuerteventura, Spain, ²Miguel Hernández University of Elche, Alicante, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Gout and calcium pyrophosphate crystal deposition disease (CPPD) are frequent in hospital settings. In Spain, last available data (2005-2015) indicated that 0.48% of hospital…
Abstract Number: 0744 • ACR Convergence 2025
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Delia Fernandez-Lozano¹, Marta Domínguez-Álvaro², Javier Narváez³, Noemí Garrido⁴, Eugenio de Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez Martín¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro Cáceres¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, rafeal Benito-Melero¹⁶, Maria Garcia-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ⁹Hospital Universitario Donostia, San Sebastian, Spain, ¹⁰Hospital León, LEON, Castilla y Leon, Spain, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Galdakao-Usansolo University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁶MD, barcelona, Spain, ¹⁷Hospital Ramón y Cajal, Madrid, Spain, ¹⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁹Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…
Abstract Number: 1251 • ACR Convergence 2024
Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Xenofon Baraliakos¹, Victoria Navarro Compán², Elena Nikiphorou³, Thao Pham⁴, Francesco Ciccia⁵, Megan Hughes⁶, Bruno Kranz⁶, Anna Jus⁷, Chris Watson⁷, Jo Lowe⁸ and Sofia Ramiro⁹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³King's College London, London, United Kingdom, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵Università degli studi della Campania Luigi Vanvitelli, Naples, Italy, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Alfasigma S.p.A., Bologna, Italy, ⁸Axial Spondyloarthritis International Federation, London, United Kingdom, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…
Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Anisha M. Patel¹, Carmen Ng¹, Lisa Lindsay¹, Zhiyu Xia², William F. Pendergraft III³ and Maria Dall'Era⁴, ¹Genentech, Inc., South San Francisco, ²Genentech, Inc., Sou, ³Genentech, Inc., Chapel Hill, NC, ⁴UCSF, Corte Madera, CA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
Abstract Number: 1747 • ACR Convergence 2024
Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis
Parmita Das¹, Snehin Rajkumar², Eric Yen³ and Ram Singh⁴, ¹University of California Los Angeles, Saint Johns, ²UCLA David Geffen School of Medicine, Irvine, CA, ³UCLA, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic debilitating disease affecting up to 1% of the US population and has variable outcomes by race/ethnicity. We analyzed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].